TMCnet News
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Tokai Pharmaceuticals, Inc. and Certain Officers and Directors -- TKAILevi & Korsinsky, LLP announces that it has commenced an investigation of Tokai Pharmaceuticals, Inc. ("Tokai Pharmaceuticals" or the "Company") (NASDAQGM:TKAI) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors. On July 26, 2016, Tokai announced it would end a late-stage trial of its prostate cancer therapy candidate galeterone, saying it believed the stage 3 study would not meet its primary endpoint. Following this news, Tokai shares fell from a close of $5.20 on July 25, 2016, to a close of $1.10 on July 26, 2016. To obtain additional information about the investigation, go to: http://zlk.9nl.com/tokai-pharmaceuticals-tkai or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
View source version on businesswire.com: http://www.businesswire.com/news/home/20160728006152/en/ |
